This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Four Charts Tear Apart Peregrine Pharma's Quarterly Spin Job

Stocks in this article: PPHM

TUSTIN, Calif. ( TheStreet) -- Here's a reality check -- illustrated with charts -- which will help interpret Peregrine Pharmaceuticals' (PPHM) corporate update and financial report for the first quarter in its 2014 fiscal year issued Monday night.

Peregrine CEO Steven King:

Over the last few months, we have been building on the excitement created by the immunotherapy mechanism data and have been actively engaging scientists and key opinion leaders in the field of immunology, with the goal of engaging their expertise as we advance the bavituximab program. We have been extremely pleased as to how these data have been received and the enthusiasm exhibited from the potential of bavituximab. We are looking forward to continuing these activities and supplementing these discussions with preclinical data for ongoing studies expected to come out in the next few months. PPHM Chart PPHM data by YCharts


In addition to the immunotherapy research, there has been significant interest in the results presented at ASCO showing an 84% tumor response rate in HER2-negative breast cancer patients, highlighting the potential of bavituximab in this difficult-to-treat indication. Of course, our key company goal remains initiating the Phase III second-line non-small cell lung cancer study, which we have named the SUNRISE trial, by year end.

Significant interest? He must mean in every other biotech stock except Peregrine: PPHM Chart PPHM data by YCharts

Joseph Shan, vice president of clinical and regulatory affairs:

The clinical activities during the quarter focused on preparations for the start of our pivotal Phase III trial in non-small cell lung cancer and supporting the preclinical proof-of-concept program that Jeff just outlined for you. The Phase III trial is named SUNRISE, an acronym which stands for Stimulating Immune Response through Bavituximab in a Phase III Lung Cancer Study.

SUNRISE also stands for this:

Paul Lytle, chief financial officer:

During the recent quarter, our contract manufacturing business, Avid Bioservices, generated just over $4.5 million in contract manufacturing revenue. This is a solid start to fiscal year '14, and we expect contract manufacturing revenue for the entire fiscal year '14 to be between $18 million and $22 million based on current commitments. PPHM Revenue Quarterly Chart PPHM Revenue Quarterly data by YCharts

By the way, Peregrine's contract manufacturing revenue for fiscal year 2013 totaled $21.3 million, so the company is guiding down for this fiscal year.


Now turning to our cash position. We continued to maintain a balanced financial approach, ending the quarter with $41.6 million in cash compared to $35.2 million in cash at fiscal year end, April 30, 2013. This provides us sufficient capital to fund our operations through at least the first quarter of fiscal year '15 based on our current financial projections, giving us the needed flexibility to initiate the upcoming Phase III trial in second-line lung cancer while strengthening our position as we evaluate other opportunities, including ongoing partnering discussions.

But what about the cost of running the SUNRISE clinical trial? Isn't it expensive?


Yes. Generally, it's -- Phase III trials, George, are approximately about $100,000 a patient. So it's 600 patients. You're looking at around $60 million.

The trial will cost $60 million but Peregrine has $41.6 million in the bank to cover all corporate expenses. Expect this curve to continue moving up and to the right PPHM Average Diluted Shrs Outs Quarterly Chart PPHM Average Diluted Shrs Outs Quarterly data by YCharts

Regarding those "partnering discussions": Remember when Peregrine promised to land a partner for bavituximab before starting the phase III trial?

CFO Lytle in September 2012:

Our stated goal is to have a partner on board before we start the Phase III trial and preferably, before the end of Phase II meeting with the FDA, as we would like our future partner to be a part of that important meeting.

And CEO King, speaking last night:

Yes, so I think we've put ourselves in position where it's our intention to go ahead and be able to start the clinical study and to, in fact, complete the clinical study, if necessary, on our own.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs